Selective reporting biases in cancer prognostic factor studies

Journal of the National Cancer Institute

Volumn 97, Issue 14, 2005, Pages 1043-1055

  Kyzas, Panayiotis A ^a   Loizou, Konstantinos T ^b   Ioannidis, John P A ^a,b,c  

^a UNIVERSITY OF IOANNINA   (Greece)

^b INSTITUTE OF COMPUTER SCIENCE   (Greece)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TUMOR MARKER;

CANCER MORTALITY; CANCER RESEARCH; CANCER SURVIVAL; CONFIDENCE INTERVAL; EMBASE; HEAD AND NECK CANCER; HUMAN; INFORMATION PROCESSING; MALIGNANT NEOPLASTIC DISEASE; MEDICAL LITERATURE; MEDLINE; PRIORITY JOURNAL; PROGNOSIS; PUBLICATION; REVIEW; SQUAMOUS CELL CARCINOMA; STANDARDIZATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; AGED; ARTICLE; CHEMISTRY; CLINICAL TRIAL; EPIDEMIOLOGY; FEMALE; HEAD AND NECK TUMOR; LYMPH NODE METASTASIS; MALE; META ANALYSIS; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTION AND FORECASTING; PUBLISHING; RISK; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; UNITED STATES;

AGED; CARCINOMA, SQUAMOUS CELL; CONFIDENCE INTERVALS; EPIDEMIOLOGIC RESEARCH DESIGN; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PUBLICATION BIAS; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UNITED STATES;

EID: 23244461458     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dji184     Document Type: Review

References (122)

1. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994;69:979-85.
2. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004;4:309-14.
3. Altman DG, Lyman GH. Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat 1998;52: 289-303.
4. Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ 2001;323:224-8.
5. Dickersin K, Chan S, Chalmers TC, Sacs HS, Smith HJ. Publication bias and clinical trials. Control Clin Trials 1987;8:343-53.
6. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994;86:829-35.
7. Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA 1989;86:8763-7.
8. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001;1:233-40.
9. Pakos EE, Kyzas AP, Ioannidis JP. Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: A meta-analysis. Clin Cancer Res 2004;10:6208-14.
10. Greenberg JS, El Naggar AK, Mo V, Roberts D, Myers JN. Disparity in pathologic and clinical lymph node staging in oral tongue carcinoma. Implication for therapeutic decision-making. Cancer 2003;98:508-15.
11. Pettiti DB. Meta-analysis, decision analysis and cost-effectiveness analysis. 2nd edition, New York (NY), Oxford University Press; 1999.
12. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127:820-6.
13. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
14. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: Power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000;53:1119-29.
15. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
16. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
17. Sauter ER, Ridge JA, Gordon J, Eisenberg BL. p53 overexpression correlates with increased survival in patients with squamous carcinoma of the tongue base. Am J Surg 1992;164:651-3.
18. Leedy DA, Trune DR, Kronz JD, Weidner N, Cohen JI. Tumor angiogenesis, the p53 antigen, and cervical metastasis in squamous carcinoma of the tongue. Otolaryngol Head Neck Surg 1994;111:417-22.
19. Frank JL, Bur ME, Garb JL, Kay S, Ware JL, Sismanis A, et al. p53 tumor suppressor oncogene expression in squamous cell carcinoma of the hypopharynx. Cancer 1994;73:181-6.
20. Ahomadegbe JC, Barrois M, Fogel S, Le Bihan ML, Douc-Rasy S, Duvillard P, et al. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 1995;10:1217-27.
21. Wilson GD, Richman PI, Dische S, Saunders MI, Robinson B, Daley FM, et al. p53 status of head and neck cancer: Relation to biological characteristics and outcome of radiotherapy. Br J Cancer 1995;71:1248-52.
22. Bradford CR, Zhu S, Wolf GT, Poore J, Fisher SG, Beals T, et al. Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer. Otolaryngol Head Neck Surg 1995;113:408-12.
23. Nadal A, Campo E, Pinto J, Mallofre C, Palacin A, Arias C, et al. p53 expression in normal, dysplastic, and neoplastic laryngeal epithelium. Absence of a correlation with prognostic factors. J Pathol 1995;175:181-8.
24. Spafford ME, Koeppe J, Pan Z, Archer PG, Meyers AD, Franklin WA. Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1996;122:627-32.
25. Caminero MJ, Nunez F, Suarez C, Ablanedo P, Riera JR, Dominguez F. Detection of p53 protein in oropharyngeal carcinoma. Prognostic implications. Arch Otolaryngol Head Neck Surg 1996;122:769-72.
26. Chiba I, Shindoh M, Yasuda M, Yamazaki Y, Amemiya A, Sato Y, et al. Mutations in the p53 gene and human papillomavirus infection as significant prognostic factors in squamous cell carcinomas of the oral cavity. Oncogene 1996;12:1663-8.
27. Awwad S, Jaros E, Somes J, Lunec J. P53 overexpression in head and neck carcinoma and radiotherapy results. Int. J Radiat Oncol Biol Phys 1996;34:323-32.
28. Koch WM, Brennan JA, Zahurak M, Goodman SN, Westra WH, Schwab D, et al. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:1580-6.
29. Kokoska MS, Piccirillo JF, el-Mofty SK, Emami B, Haughey BH, Schoinick SB. Prognostic significance of clinical factors and p53 expression in patients with glottic carcinoma treated with radiation therapy. Cancer 1996;78:1693-700.
30. Kusama K, Okutsu S, Takeda A, Himiya T, Kojima A, Kidokoro Y, et al. p53 gene alterations and p53 protein in oral epithelial dysplasia and squamous cell carcinoma. J Pathol 1996;78:415-21.
31. Haraf DJ, Nodzenski E, Brachman D, Mick R, Montag A, Graves D, et al. Human papilloma virus and p53 in head and neck cancer: Clinical correlates and survival. Clin Cancer Res 1996;2:755-62.
32. Dunphy CH, Dunphy FR, Boyd JH, Varvares MA, Kim HJ, Lowe V, et al. Expression of p53 protein in advanced head and neck squamous cell carcinoma before and after chemotherapy. Arch Otolaryngol Head Neck Surg 1997;123:1223-5.
33. Hirvikoski P, Kumpulainen E, Virtaniemi J, Johansson R, Haapasalo H, Marin S, et al. p53 expression and cell proliferation as prognostic factors in laryngeal squamous cell carcinoma. J Clin Oncol 1997;15:3111-20.
34. Cutilli T, Papola F, Corbacelli A. p53 overexpression and mutation, chemoresistance and patient survival in oral and maxillofacial squamous cell carcinoma. J Chemother 1997;9:123-4.
35. Veneroni S, Silvestrini R, Costa A, Salvatori P, Faranda A, Molinari R. Biological indicators of survival in patients treated by surgery for squamous cell carcinoma of the oral cavity and oropharynx. Oral Oncol 1997;33: 408-13.
36. Sommer T, Olofsson J. Significance of p53, PCNA and Ki-67 in the prognosis of squamous cell carcinoma of the oral cavity. Laryngorhinootologie 1997;76:189-96.
37. Olshan AF, Weissler MC, Pei H, Conway K, Anderson S, Fried DB, et al. Alterations of the p16 gene in head and neck cancer: Frequency and association with p53, PRAD-1 and HPV. Oncogene 1997;14:811-8.
38. Stoll C, Baretton G, Lohrs U. The influence of p53 and associated factors on the outcome of patients with oral squamous cell carcinoma. Virchows Arch 1998;433:427-33.
39. Tatemoto Y, Osaki T, Yoneda K, Yamamoto T, Ueta E, Kimura T. Expression of p53 and p21 proteins in oral squamous cell carcinoma: Correlation with lymph node metastasis and response to chemoradiotherapy. Pathol Res Pract 1998;194:821-30.
40. Hegde PU, Brenski AC, Caldarelli DD, Hutchinson J, Panje WR, Wood NB, et al. Tumor angiogenesis and p53 mutations: Prognosis in head and neck cancer. Arch Otolaryngol Head Neck Surg 1998; 124:80-5.
41. Mineta H, Borg A, Dictor M, Wahlberg P, Akervall J, Wennerberg J. p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma. Br J Cancer 1998;78:1084-90.
42. Pruneri G, Pignataro L, Carboni N, Ronchetti D, Cesana BM, Ottaviani A, et al. Clinical relevance of p53 and bcl-2 protein over-expression in laryngeal squamous-cell carcinoma. Int J Cancer 1998;79:263-8.
43. Erber R, Conradt C, Homann N, Enders C, Finckh M, Dietz A, et al. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene 1998;16:1671-9.
44. Riethdorf S, Friedrich RE, Suhwold J, Ostwald C, Barten M, Gogacz P, et al. [p53 mutations and HPV infections in squamous epithelial carcinomas of the head-neck region. Long-term follow-up]. Mund Kiefer Gesichtschir 1998;2:30-4.
45. Kaur J, Srivastava A, Ralhan R. Prognostic significance of p53 protein overexpression in bete1- and tobacco-related oral oncogenesis. Int J Cancer 1998;79:370-5.
46. Ma L, Ronai A, Riede UN, Kohler G. Clinical implication of screening p53 gene mutations in head and neck squamous cell carcinomas. J Cancer Res Clin Oncol 1998;124:389-96.
47. Gandour-Edwards R, Trock BJ, Gumerlock P, Donald PJ. Heat shock protein and p53 expression in head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 1998;118:610-15.
48. Maeda T, Matsumura S, Hiranuma H, Jikko A, Furukawa S, Ishida T, et al. Expression of vascular endothelial growth factor in human oral squamous cell carcinoma: Its association with tumour progression and p53 gene status. J Clin Pathol 1998;51:771-5.
49. Jin YT, Kayser S, Kemp BL, Ordonez NG, Tucker SL, Clayman GL, et al. The prognostic significance of the biomarkers p21WAF1/CIP1, p53, and bcl-2 in laryngeal squamous cell carcinoma. Cancer 1998;82:2159-65.
50. Lera J, Lara PC, Perez S, Cabrera JL, Santana C. Tumor proliferation, p53 expression, and apoptosis in laryngeal carcinoma: Relation to the results of radiotherapy. Cancer 1998;83:2493-501.
51. Pai HH, Rochon L, Clark B, Black M, Shenouda G. Overexpression of p53 protein does not predict local-regional control or survival in patients with early-stage squamous cell carcinoma of the glottic larynx treated with radiotherapy. Int J Radiat Oncol Biol Phys 1998;41:37-42.
52. Ibrahim SO, Lillehaug JR, Johannessen AC, Liavaag PG, Nilsen R, Vasstrand EN. Expression of biomarkers (p53, transforming growth factor alpha, epidermal growth factor receptor, c-erbB-2/neu and the proliferative cell nuclear antigen in oropharyngeal squamous cell carcinomas. Oral Oncol 1999;35:302-13.
53. Yao L, Iwai M, Furuta I. Correlations of bcl-2 and p53 expression with the clinicopathological features in tongue squamous cell carcinomas. Oral Oncol 1999;35:56-62.
54. Unal OF, Ayhan A, Hosal AS. Prognostic value of p53 expression and histopathological parameters in squamous cell carcinoma of oral tongue. J Laryngol Otol 1999;113:446-50.
55. Haas S, Bosch FX, Klein-Kuhne W, Nollert J, Rudat V, Conradt C, et al. [Prognostic significance of cell-cycle regulatory proteins for outcome after primary radiochemotherapy in patients with advanced head and neck cancer]. HNO 1999;47:777-86.
56. Pulkkinen JO, Klemi P, Martikainen P, Grenman R. Apoptosis in situ, p53, bcl-2 and AgNOR counts as prognostic factors in laryngeal carcinoma. Anticancer Res 1999;19:703-7.
57. Taylor D, Koch WM, Zahurak M, Shah K, Sidransky D, Westra WH. Immunohistochemical detection of p53 protein accumulation in head and neck cancer: Correlation with p53 gene alterations. Hum Pathol 1999;30: 1221-5.
58. Welkoborsky HJ, Gluckman JL, Jacob R, Bernauer H, Mann W. Tumor biologic prognostic parameters in T1N0M0 squamous cell carcinoma of the oral cavity. Laryngorhinootologie 1999;78:131-8.
59. Chomchai JS, Du W, Sarkar FH, Li YW, Jacobs JR, Ensley JF, et al. Prognostic significance of p53 gene mutations in laryngeal cancer. Laryngoscope 1999;109:455-9.
60. Chiang CP, Huang JS, Wang JT, Liu BY, Kuo YS, Hahn LJ, et al. Expression of p53 protein correlates with decreased survival in patients with areca quid chewing and smoking-associated oral squamous cell carcinomas in Taiwan. J Oral Pathol Med 1999;28:72-6.
61. Xie X, Clausen OP, De Angelis P, Boysen M. The prognostic value of spontaneous apoptosis, Bax, Bcl-2, and p53 in oral squamous cell carcinoma of the tongue. Cancer 1999;86:913-20.
62. Fujieda S, Inuzuka M, Tanaka N, Sunaga H, Fan GK, Ito T, et al. Expression of p27 is associated with Bax expression and spontaneous apoptosis in oral and oropharyngeal carcinoma. Int J Cancer 1999;84:315-20.
63. Kurokawa H, Yamashita Y, Takeda S, Miura K, Murata T, Kajiyama M. The expression of proliferating cell nuclear antigen (PCNA) and p 53 protein correlate with prognosis of patients with oral squamous cell carcinoma. Fukuoka Igaku Zasshi 1999;90:6-13.
64. Narayana A, Vaughan AT, Kathuria S, Fisher SG, Walter SA, Reddy SP. P53 overexpression is associated with bulky tumor and poor local control in T1 glottic cancer. Int. J Radiat Oncol Biol Phys 2000;146:21-6.
65. Obata A, Eura M, Sasaki J, Saya H, Chikamatsu K, Tada M, et al. Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx. Int J Cancer 2000;89:187-93.
66. Jeannon JP, Soames J, Lunec J, Awwad S, Ashton V, Wilson JA. Expression of cyclin-dependent kinase inhibitor p21(WAF1) and p53 tumour suppressor gene in laryngeal cancer. [published erratum appears in: Clin Otolaryngol 2000;25:431.] Clin Otolaryngol 2000;25:23-7.
67. Cabelguenne A, Blons H, de Waziers I, Carnot F, Houllier AM, Soussi T, et al. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: A prospective series. J Clin Oncol 2000;18:1465-73.
68. Riedel F, Gotte K, Schwalb J, Schafer C, Hormann K. Vascular endothelial growth factor expression correlates with p53 mutation and angiogenesis in squamous cell carcinoma of the head and neck. Acta Otolaryngol 2000;120:105-11.
69. Shima K, Kobayashi I, Saito I, Kiyoshima T, Matsuo K, Ozeki S, et al. Incidence of human papillomavirus 16 and 18 infection and p53 mutation in patients with oral squamous cell carcinoma in Japan. Br J Oral Maxillofac Surg 2000;38:445-50.
70. Jackel MC, Sellmann L, Dorudian MA, Youssef S, Fuzesi L. Prognostic significance of p53/bcl-2 co-expression in patients with laryngeal squamous cell carcinoma. Laryngoscope 2000;110:1339-45.
71. Ostwald C, Gogacz P, Hillmann T, Schweder J, Gundlach K, Kundt G, et al. p53 mutational spectra are different between squamous-cell carcinomas of the lip and the oral cavity. Int J Cancer 2000;88:82-6.
72. Grabenbauer GG, Muhlfriedel C, Rodel F. Squamous cell carcinoma of the oropharynx: Ki-67 and p53 can identify patients at high risk for local recurrence after surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 2000;48:1041-50.
73. Lam KY, Ng IO, Yuen AP, Kwong DL, Wei W. Cyclin D1 expression in oral squamous cell carcinomas: Clinicopathological relevance and correlation with p53 expression. J Oral Pathol Med 2000;29:167-72.
74. Gonzalez-Moles MA, Galindo P, Gutierrez-Fernandez J, Sanchez-Fernandez E, Rodriguez-Archilla A, Ruiz-Avila I, et al. P53 protein expression in oral squamous cell carcinoma. Survival analysis. Anticancer Res 2001;21:2889-94.
75. Friedman M, Lim JW, Manders E, Schaffner AD, Kirshenbaum GL, Tanyeri HM, et al. Prognostic significance of Bcl-2 and p53 expression in advanced laryngeal squamous cell carcinoma. Head Neck 2001;23:280-5.
76. Kerdpon D, Sriplung H, Kietthubthew S. Expression of p53 in oral squamous cell carcinoma and its association with risk habits in southern Thailand. Oral Oncol 2001;37:553-7.
77. Kazkayasi M, Hucumenoglu S, Siriner GI, Hucumenoglu M. Over-expression of p53 and c-erbB-2 oncoproteins in laryngeal carcinoma. Eur Arch Otorhinolaryngol 2001;258:329-35.
78. Koelbl O, Rosenwald A, Haberl M, Muller J, Reuther J, Flentje M. p53 and Ki-67 as predictive markers for radiosensitivity in squamous cell carcinoma of the oral cavity? an immunohistochemical and clinicopathologic study. Int J Radiat Oncol Biol Phys 2001;49:147-54.
79. Alsner J, Sorensen SB, Overgaard J. TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. Radiother Oncol 2001;59:179-85.
80. Georgiou A, Gomatos IP, Ferekidis E, Syrigos K, Bistola V, Giotakis J, et al. Prognostic significance of p53, bax and bcl-2 gene expression in patients with laryngeal carcinoma. Eur J Surg Oncol 2001;27:574-80.
81. Smith BD, Smith GL, Carter D, DiGiovanna MP, Kasowitz KM, Sasaki CT, et al. Molecular marker expression in oral and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2001;127:780-5.
82. Grammatica L, Piepoli S, D'Auria C, Achille G, Marzullo F, Zito FA, et al. Primary tumours neoangiogenesis and P53 expression in oral carcinoma patients. J Exp Clin Cancer Res 2001;20:225-30.
83. Couture C, Raybaud-Diogene H, Tetu B, Bairati I, Murry D, Allard J, et al. p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer 2002;94:713-22.
84. Nagler RM, Kerner H, Laufer D, Ben-Eliezer S, Minkov I, Ben-Itzhak O. Squamous cell carcinoma of the tongue: The prevalence and prognostic roles of p53, Bcl-2, c-erbB-2 and apoptotic rate as related to clinical and pathological characteristics in a retrospective study. Cancer Lett 2002;186:137-50.
85. Kuropkat C, Venkatesan TK, Caldarelli DD, Panje WR, Hutchinson J, Preisler HD, et al. Abnormalities of molecular regulators of proliferation and apoptosis in carcinoma of the oral cavity and oropharynx. Auris Nasus Larynx 2002;29:165-74.
86. Sisk EA, Soltys SG, Zhu S, Fisher SG, Carey TE, Bradford CR. Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. Head Neck 2002;24:841-9.
87. Geisler SA, Olshan AF, Weissler MC, Cai J, Funkhouser WK, Smith J, et al. p16 and p53 Protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer. Clin Cancer Res 2002;8:3445-53.
88. Tabor MP, van Houten VM, Kummer JA, Vosjan MJ, Vlasblom R, Snow GB, et al. Discordance of genetic alterations between primary head and neck tumors and corresponding metastases associated with mutational status of the TP53 gene. Genes Chromosomes Cancer 2002;33:168-77.
89. Khademi B, Shirazi FM, Vasei M, Doroudchi M, Gandomi B, Modjtahedi H, et al. The expression of p53, c-erbB-1 and c-erbB-2 molecules and their correlation with prognostic markers in patients with head and neck tumors. Cancer Lett 2002;184:223-30.
90. Takes RP, Baatenburg De Jong RJ, Alles MJ, Meeuwis CA, Marres HA, Knegt PP, et al. Markers for nodal metastasis in head and neck squamous cell cancer. Arch Otolaryngol Head Neck Surg 2002;128:512-8.
91. Teppo H, Soini Y, Melkko J, Koivunen P, Alho OP. Prognostic factors in laryngeal carcinoma: The role of apoptosis, p53, proliferation (Ki-67) and angiogenesis. APMIS 2003;111:451-7.
92. Vora HH, Shah NG, Patel DD, Trivedi TI, Chikhlikar PR. Prognostic significance of biomarkers in squamous cell carcinoma of the tongue: multivariate analysis. J Surg Oncol 2003;82:34-50.
93. Vielba R, Bilbao J, Ispizua A, Zabalza I, Alfaro J, Rezola R, et al. p53 and cyclin D1 as prognostic factors in squamous cell carcinoma of the larynx. Laryngoscope 2003;113:167-72.
94. Carlos de Vicente J, Junquera Gutierrez LM, Zapatero AH, Fresno Forcelledo MF, Hernandez-Vallejo G, Lopez Arranz JS. Prognostic significance of p53 expression in oral squamous cell carcinoma without neck node metastases. Head Neck 2004;26:22-30.
95. Jayasurya R, Francis G, Kannan S, Lekshminarayanan K, Nalinakumari KR, Abraham T, et al. p53, p16 and cyclin D1: Molecular determinants of radiotherapy treatment response in oral carcinoma. Int J Cancer 2004;109:710-6.
96. Meert AP, Martin B, Delmotte P, Berghmans T, Lafitte JJ, Mascaux C, et al. The role of EGF-R expression on patient survival in lung cancer: A systematic review with meta-analysis. Eur Respir J 2002;20:975-81.
97. Meert AP, Paesmans M, Martin B, Delmotte P, Berghmans T, Verdebout JM, et al. The role of microvessel density on the survival of patients with lung cancer: A systematic review of the literature with meta-analysis. Br J Cancer 2002;87:694-701.
98. Meert AP, Martin B, Paesmans M, Berghmans T, Mascaux C, Verdebout JM, et al. The role of HER-2/neu expression on the survival of patients with lung cancer: A systematic review of the literature. Br J Cancer 2003;89:959-65.
99. Pakos EE, Ioannidis JP. The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis. Cancer 2003;98:581-9.
100. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: A systematic, quantitative review. Cancer 2001;91:2214-21.
101. Huncharek M, Kupelnick B, Geschwind JF, Caubet JF. Prognostic significance of p53 mutations in non-small cell lung cancer: A meta-analysis of 829 cases from eight published studies. Cancer Lett 2000;153:219-26.
102. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: A meta-analysis. Clin Cancer Res 2000;6:4055-63.
103. Vansteenkiste JF, De Leyn PR, Deneffe GJ, Lerut TE, Demends MG. Clinical prognostic factors in surgically treated stage IIIA-N2 non-small cell lung cancer: Analysis of the literature. Lung Cancer 1998;19:3-13.
104. Riley RD, Heney D, Jones DR, Sutton AJ, Lambert PC, Abrams KR, et al. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res 2004;10:4-12.
105. Martin B, Paesmans M, Berghmans T, Branle F, Ghisdal L, Mascaux C, et al. Role of Bcl-2 as a prognostic factor for survival in lung cancer: A systematic review of the literature with meta-analysis. Br J Cancer 2003;89:55-64.
106. Uzzan B, Nicolas P, Cucherat M, Perret GY. Microvessel density as a prognostic factor in women with breast cancer: A systematic review of the literature and meta-analysis. Cancer Res 2004;64:2941-55.
107. Funke I, Schraut W. Meta-analyses of studies on bone marrow micrometastases: An independent prognostic impact remains to be substantiated. J Clin Oncol 1998;16:557-66.
108. Choma D, Daures JP, Quantin X, Pujol JL. Aneuploidy and prognosis of non-small-cell lung cancer: A meta-analysis of published data. Br J Cancer 2001;85:14-22.
109. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, et al. Role of p53 as a prognostic factor for survival in lung cancer: A systematic review of the literature with a meta-analysis. Eur Respir J 2001;18:705-19.
110. Huncharek M, Muscat J, Geschwind JF. K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: A combined analysis of 881 cases. Carcinogenesis 1999;20:1507-10.
111. Riley RD, Burchill SA, Abrams KR, Heney D, Sutton AJ, Jones DR, et al. A systematic review of molecular and biological markers in tumours of the Ewing's sarcoma family. Eur J Cancer 2003;39:19-30.
112. Pharoah PD, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: A meta-analysis. Br J Cancer 1999;80:1968-73.
113. Ryu SY, Kim CB, Nam CM, Park JK, Kim KS, Park J, et al. Is body mass index the prognostic factor in breast cancer? A meta-analysis. J Korean Med Sci 2001;16:610-4.
114. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Stat Med 2001;20:641-54.
115. Ioannidis JP. Genetic associations: False or true? Trends Mol Med 2003;9:135-8.
116. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291:2457-65.
117. Bogardus ST Jr, Concato J, Feinstein AR. Clinical epidemiological quality in molecular genetic research: The need for methodological standards. JAMA 1999;281:1919-26.
118. Ioannidis JP, Rosenberg PS, Goedert JJ, O'Brien TR. Commentary: meta-analysis of individual participants' data in genetic epidemiology. Am J Epidemiol 2002;156:204-10.
119. Ntzani EE, Ioannidis JP. Predictive ability of DNA microarrays for cancer outcomes and correlates: An empirical assessment. Lancet 2003;362: 1439-44.
120. Lau J, Ioannidis JP, Schmid CH. Summing up evidence: One answer is not always enough. Lancet 1998;351:123-7.
121. Stroup DE, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology MOOSE group. JAMA 2000;283:2008-12.
122. Ioannidis JP. Why most published research findings are false. PLoS Med. In press 2005.